| Literature DB >> 27989851 |
Pichamol Jirapinyo1, Christopher C Thompson2.
Abstract
Obesity is a worsening pandemic with numerous related comorbid illnesses. Conservative management including lifestyle modification and medications have limited efficacy. In contradistinction, bariatric surgery is effective, however, with substantial cost and non-negligible morbidity and mortality. As such, a small percentage of eligible patients undergo surgery. Over the past decade, endoscopic bariatric and metabolic therapies have been introduced as a less invasive option for the treatment of obesity and its related comorbid illnesses. This article reviews major endoscopic bariatric and metabolic therapies, their surgical analogues, and proposed mechanisms of action. Clinical trial data for each device also are discussed.Entities:
Keywords: Aspire; Bariatric; Diabetes; Duo; EBMT; EBT; ESG; EndoBarrier; Endoscopic Sleeve Gastroplasty; Endoscopy; GLP-1; Gastric Balloon; Ghrelin; IMAS; Incretin; Magnetic; Metabolic; Obalon; Obesity; Orbera; POSE; PYY
Mesh:
Year: 2016 PMID: 27989851 PMCID: PMC5444453 DOI: 10.1016/j.cgh.2016.10.021
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382